Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Homologous or heterologous COVID-19 booster safety and immunogenicity study
RBR-5y9y7p7Phase 4Recruiting
- Sponsor
- Secretaria Municipal de Saúde do Rio de Janeiro
- Start
- Oct 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of tozinameran, ChAdOx1 nCoV-19, Ad26.COV2.S and coronavac in coronavirus disease 2019 (COVID-19) (9 cohorts), sponsored by Secretaria Municipal de Saúde do Rio de Janeiro. Primary endpoints: Safety and Humoral immunogenicity. Started Oct 2021; status: recruiting.
02
Drugs
tozinameranChAdOx1 nCoV-19Ad26.COV2.Scoronavac
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on RBR-5y9y7p7.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-5y9y7p7.